Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | INO-5401 |
| Trade Name | |
| Synonyms | INO5401|INO 5401 |
| Drug Descriptions |
INO-5401 is a DNA plasmid engineered to encode for WT1, hTERT, and PSMA, which potentially enhances antitumor immune response (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 2004, Journal for ImmunoTherapy of Cancer 2020;8). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C148480 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Atezolizumab + INO-5401 + Rocakinogene sifuplasmid | Atezolizumab INO-5401 Rocakinogene sifuplasmid | 0 | 1 |
| Cemiplimab + INO-5401 + Rocakinogene sifuplasmid + Temozolomide | Cemiplimab INO-5401 Rocakinogene sifuplasmid Temozolomide | 0 | 1 |
| INO-5401 | INO-5401 | 0 | 1 |
| INO-5401 + Rocakinogene sifuplasmid | INO-5401 Rocakinogene sifuplasmid | 0 | 1 |